These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 32598976)
1. Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials. Reda M; Bagley AF; Zaidan HY; Yantasee W Radiother Oncol; 2020 Sep; 150():225-235. PubMed ID: 32598976 [TBL] [Abstract][Full Text] [Related]
2. Integrating chemoradiation and molecularly targeted therapy. Wahl DR; Lawrence TS Adv Drug Deliv Rev; 2017 Jan; 109():74-83. PubMed ID: 26596559 [TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Toulany M; Rodemann HP Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967 [TBL] [Abstract][Full Text] [Related]
4. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC). Azoury SC; Gilmore RC; Shukla V Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787 [TBL] [Abstract][Full Text] [Related]
5. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792 [TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
7. The CD73/Ado System-A New Player in RT Induced Adverse Late Effects. de Leve S; Wirsdörfer F; Jendrossek V Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623231 [TBL] [Abstract][Full Text] [Related]
8. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma. Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT Cells; 2020 Mar; 9(3):. PubMed ID: 32197467 [TBL] [Abstract][Full Text] [Related]
9. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity? Wirsdörfer F; de Leve S; Jendrossek V Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587 [TBL] [Abstract][Full Text] [Related]
10. Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer? Césaire M; Thariat J; Candéias SM; Stefan D; Saintigny Y; Chevalier F Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30487462 [TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Marquard FE; Jücker M Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230 [TBL] [Abstract][Full Text] [Related]
12. Targeting AKT/PKB to improve treatment outcomes for solid tumors. Iida M; Harari PM; Wheeler DL; Toulany M Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136 [TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Burris HA Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372 [TBL] [Abstract][Full Text] [Related]
14. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer. Sacco PC; Maione P; Guida C; Gridelli C Curr Clin Pharmacol; 2017; 12(1):4-10. PubMed ID: 27908252 [TBL] [Abstract][Full Text] [Related]
15. Advanced nanomaterials targeting hypoxia to enhance radiotherapy. Li J; Shang W; Li Y; Fu S; Tian J; Lu L Int J Nanomedicine; 2018; 13():5925-5936. PubMed ID: 30319257 [TBL] [Abstract][Full Text] [Related]
16. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561 [TBL] [Abstract][Full Text] [Related]